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Extinct type of human parvovirus B19 persists
in tonsillar B cells
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Parvovirus B19 (B19V) DNA persists lifelong in human tissues, but the cell type harbouring it
remains unclear. We here explore B19V DNA distribution in B, Tand monocyte cell lineages of
recently excised tonsillar tissues from 77 individuals with an age range of 2–69 years. We
show that B19V DNA is most frequent and abundant among B cells, and within them we ﬁnd
a B19V genotype that vanished from circulation 440 years ago. Since re-infection or
re-activation are unlikely with this virus type, this ﬁnding supports the maintenance of
pathogen-speciﬁc humoral immune responses as a consequence of B-cell long-term survival
rather than continuous replenishment of the memory pool. Moreover, we demonstrate the
mechanism of B19V internalization to be antibody dependent in two B-cell lines as well as in
ex vivo isolated tonsillar B cells. This study provides direct evidence for a cell type accountable
for B19V DNA tissue persistence.
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P
arvovirus B19 (B19V) infection affects most often children,
with exposure rates generally over 50% by adulthood1.
The virus circulates worldwide, with current infections
mainly due to genotype 1 (ref. 2). Of the other two variants
that are known, genotype 2 disappeared from circulation around
1970 (refs 3,4) and genotype 3 has been described to circulate
endemically in some regions such as Ghana, Brasil and India5–8.
After primary infection, B19V DNA persists lifelong in several
human tissues such as tonsils, testicles, kidneys, muscle, salivary
glands, thyroid, skin, liver, heart, brain, bone marrow and
bone3,4,9–11. However, nothing is known on the speciﬁc cell
type(s) that harbours it throughout time.
B19V replicates in erythroid progenitor cells of the bone
marrow with primary infection occurring via the globoside
receptor and the a5b1 integrin and Ku80 co-receptors12–14 but
uptake has also been shown to occur through antibody-
dependent enhancement (ADE) in monocytes15 and endothelial
cells16. The short lifetime of these cells, however, does argue
against them being the host of this virus’ DNA for years
after primary infection. Instead, an appealing alternative may
be granted by the memory cells that reside in lymphoid organs
since their lifespan has been estimated to exceed decades based
on the length of immune protection after infection or
vaccination17.
Hence, in the present study, we evaluate the distribution of
B19V DNA in lymphoid cells of recently excised tonsillar tissues.
Moreover, we analyse the virus type present, having previously
shown11 that the B19V genotype 2 is a reliable indicator of
the age of a tissue. We found the B19V DNA to be primarily
distributed in B cells and most importantly, we detected in
four adults the extinct genotype 2, thus providing further
evidence of this cell type as long-term reservoir of B19V DNA.
This ﬁnding also enacts as a suitable marker of the longevity
of these cells. Moreover, we show ADE to be a mechanism for
B19V uptake into B cells in vitro.
Results
B19V DNA persistence in tonsils. B19V DNA has been
previously detected in human tonsils3 but the speciﬁc cell
types where it persists lifelong are still unknown. We analysed
the B19V-DNA distribution in enriched lymphoid cell suspe-
nsions of recently excised tonsillar tissues from 77 individuals
who underwent tonsillectomy at the Department of Otorhino-
laryngology-Head and Neck Surgery of Helsinki University
Hospital. Previous ﬁndings by Medina et al.18 show that
mechanical homogenization alone is not sufﬁcient to release
long-lived cells that are associated to connective tissue-rich areas
of the tonsil, such as resident plasma cells. Hence a two-step
process of tissue homogenization involving mechanical
disaggregation followed by collagenase digestion of the residual
tonsillar tissue was developed. Each of the resulting cell
suspensions was analysed independently for the presence
of B19V DNA by an in-house Pan-B19V qPCR amplifying
the NS1 region, and the viral copy numbers were normalized
to cell counts by quantiﬁcation of the single copy RNase P gene.
B19V DNA was detected in 26% (20/77) of the total
cell populations obtained by mechanical homogenization alone
as opposed to 43% (33/77) in those cells released by subsequent
collagenase digestion. Moreover, in the latter, the median
B19V-DNA copy numbers were 18-fold higher (Po0.001,
Mann–Whitney U asymptotic sig. (two-sided test; Fig. 1a)).
The B, T and monocyte/macrophage (M) cells were enriched
from each tonsillar preparation by positive selection with
magnetic beads. The cell fraction purities were: B 96.8±0.9%,
T 95.4±1.2%, M 93.9±1.9% (mean±s.d. of 6 replicates).
B19V DNA was preferentially distributed in the B cells of
the collagenase-treated preparations (33/33 individuals) which
contained also the highest viral loads: median 6.91E1 copies/1E6
cells (95% conﬁdence interval (CI): 2.26E1–9.53E1 B19V-DNA
copies /1E6 cells) as compared to 1.7E 1 copies/1E6 cells
(95% CI: 0.00–3.08) in the fraction resulting from homogeniza-
tion alone (Fig. 1c). The difference was statistically signiﬁcant
(Po0.001, Mann–Whitney U asymptotic sig. (two-sided test)).
The B19V-DNA positivity of the B-cell fractions from collage-
nase-treated tissues was conﬁrmed with a second B19V qPCR
amplifying a distinct region (VP1 gene) of the viral genome.
There was a strict correlation between both qPCRs, with similar
copy numbers (Supplementary Fig. 1).
The Pan-B19V qPCR products of the B cells released
with collagenase were sequenced to determine the persisting
B19V genotype. Strikingly, among the six B19V genopositive
adults older than 45 years of age (45 to 69; mean 55), four had
in their B cells the extinct genotype 2 (median 1.01E2 copies /1E6
cells). All other individuals (n¼ 29) had genotype 1 (Supple-
mentary Table 1).
Interestingly, two children of 6 and 8 years had at least one
log higher B19V DNA loads than all the other individuals
(3.66E3 and 9.77E3 copies/1E6 cells, respectively). In these
two subjects, the highest amounts of B19V DNA were detected
in the M population of the homogenized cell suspension
(2.50E4 and 5.38E4 copies /1E6 cells) albeit B19V-DNA levels
were high in other cell fractions as well (Supplementary Fig. 2).
These two children were IgM negative and non-viremic.
Serum samples available from 74/77 individuals were tested for
B19V-IgG and -IgM antibodies. Altogether, 42% (31/74)
were B19V-IgG positive and none were B19V-IgM positive.
The B19V-DNA prevalence in tissue and the IgG serostatus of the
individuals showed absolute correlation (Supplementary Fig. 3).
Epstein-Barr virus DNA persistence in tonsils. The prevalence
of B19V DNA was compared to that of EBV because of the
latter’s known persistence in B cells19.
The EBV-DNA prevalence was 73% (24/33) and 70% in the
B19V DNA-positive and -negative tonsils, respectively, thus
lacking signiﬁcance (P¼ 0.827, Pearson’s w2-test).
EBV DNA was found preferentially distributed in the B cells,
with a median of 2.10E2 and 1.99E2 copies/1E6 cells among the
total cell suspensions obtained with or without collagenase
treatment, respectively, in the B19V DNA-positive tonsillar
preparations (Fig. 1b,d).
B19V- and EBV-DNA persistence in circulating lymphoid cells.
The prevalences of B19V and EBV DNA among circulating
B cells were evaluated in peripheral blood mononuclear cells
(PBMCs) as well as in CD19þ cells isolated from seven
B19V-seropositive and one B19V-seronegative, asymptomatic
staff members. Both the PBMCs and B cells from all the subjects
were PCR-negative for B19V DNA, but positive for EBV DNA in
3/8 individuals (mean 7.60E1 and 4.81E2 copies / 1E6 cells in
PBMC and B cells, respectively; Supplementary Table 2).
Compared to tonsillar B cells, the circulating CD19þ cells were
globoside negative by ﬂow cytometry (Supplementary Fig. 4d).
Characterization of tonsillar B cells. The distribution of
B19V DNA among naive and memory B cells was studied from
collagenase-treated tonsillar cell suspensions of 12 individuals
with the highest copy numbers (median 1.06E2 copies/1E6 cells).
The cells were stained with anti-CD19 antibodies, to gate
the B-cell population, together with CD27 (mature) and
IgD (naive) antibodies. Four subpopulations were sorted: CD27þ
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IgD , CD27þ IgDlow, CD27þ IgDhigh, and CD27 IgDþ
(Supplementary Fig. 5a). Both the viral loads and cell counts in
the fractions were low; the only exception being two children
(previously mentioned with the highest copies in the cohort)
whose viral DNA copies were one log higher in the CD27þ
IgDhigh than in other sub-populations (Supplementary Fig. 5b,c).
Mechanism of B19V entry into B cells. ADE facilitates B19V
entry into monocytes15 and endothelial cells16, although in the
latter the process is mediated by proteins of the complement
system.
ADE was tested as a possible entry route in two B-cell lines,
Raji and GM12878, and on primary tonsillar B cells. These cells
were conﬁrmed to express by ﬂow cytometry the Fc-receptor CD32
and the B19V receptor globoside (Supplementary Fig. 4a–c).
The cells were cultured in the presence of either B19V
IgG-positive or -negative human sera, as well as of total puriﬁed
IgG preparations. Virus internalization was followed up both
by ﬂow cytometry and confocal microscopy using ﬂuorescent
B19 virus-like particles (VLP, non-infectious), consisting of
the major capsid protein VP2 (VP2-VLP-AF647). The cells
were trypsinized before analysis to trim un-speciﬁc signals by
non-internalized particles.
In GM12878 and Raji cells, the VLP uptake was detected only
in the presence of B19V-IgGþ sera at dilutions down to 1:50 or
1:100, respectively, or of corresponding total puriﬁed IgGs at
Z0.5mgml 1 (Fig. 2a–d). Raji cells showed higher and faster
uptake efﬁciency than GM12878 cells.
A reduction in the ﬂuorescence signal of 45.7% in Raji
(Po0.05, Student’s t-test) and of 42.1% in GM12878 (P¼ 0.05,
Student’s t-test) cells was observed upon blocking of the CD32
molecule with speciﬁc antibodies, thus conﬁrming internalization
via Fc receptor (Fig. 2e,f). The VP2-VLP-AF647 uptake was
also analysed in the presence of B19V-IgGþ serum before or
after heat-inactivation to evaluate the role of complement.
However, no signiﬁcant difference was observed (Fig. 2c,d).
ADE was also tested in primary tonsillar B cells from two
B19V-seronegative individuals, with capsid uptake detected
exclusively in the presence of speciﬁc B19V IgGs at concentra-
tions down to 0.5mgml 1 (Po0.01, Student’s t-test; Fig. 3a,b).
Similar results were obtained with the monocytic cell line
U937, in which B19V-ADE was ﬁrst described, although via
the CD64 receptor, thus conﬁrming the suitability of our method
to test this mechanism (Fig. 3c).
B19V-capsid internalization was substantiated in both B-cell
lines by confocal microscopy (Fig. 4a,d). The VP2-VLP-AF647
capsids localized within early endosome antigen 1 (EEA1)-
positive endosomes at the cell periphery (Fig. 4b,e). Line proﬁle
analysis conﬁrmed that the VLP and EEA1 localizations were
similar in both cell lines (Fig. 4c,f). However, the amount of VLPs
in endosomes was higher in the Raji cells than in GM12878 cells.
Altogether, our ﬁndings suggest that B19-VLPs were able to enter
the cells via an endocytic mechanism.
ADE was evaluated moreover using native ex vivo B19 viruses
from a high-titre viremic plasma at 10 particles per cell in the
presence of 1mgml 1 B19V-positive or -negative total puriﬁed IgGs
(Fig. 5a,b). In the presence of virus-speciﬁc antibodies a signiﬁcant
increase in viral DNA copy numbers was observed (Pr0.01,
Student’s t-test). Moreover, a reduction in virus internalization of
99.6% in Raji and of 85.6% in GM12878 cells was measured upon
CD32 receptor blockage (Po0.01, Student’s t-test, Fig. 5c,d).
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Figure 1 | Viral DNA copies in tonsillar tissue. B19V- and EBV-DNA copies were measured by qPCR and normalized to cell numbers with the human
single-copy gene RNase P. Top panels: median copy numbers of B19V DNA (a) and EBV DNA (b) in tonsillar cell suspensions resulting from mechanical
homogenization (n¼ 33) (black) or after collagenase treatment (n¼ 33) (light grey). The viral copy numbers between the two preparations were
signiﬁcantly different for B19V (Po0.001), while not signiﬁcant for EBV (P40.05). Bottom panels: median copy numbers of B19V DNA (n¼ 33)
(c) and EBV DNA (n¼ 24) (d) in T-, B- and monocytic cells following homogenization (black) or collagenase digestion (light grey). The viral loads in B cells
were statistically signiﬁcant between preparations for B19V (Po0.001) while not signiﬁcant for EBV (P40.05). Error bars indicate 95% conﬁdence
intervals and were determined by normal approximation. Statistical signiﬁcance was calculated with Mann–Whitney U asymptotic sig. (two-sided test).
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Discussion
We searched for cell type(s) accounting for lifelong B19V DNA
tissue persistence. Hypothesizing that long-lived lymphoid cells
may be suitable hosts, we studied the distribution of B19V DNA
in tonsillar B, T and monocyte cell lineages.
To release long-lived cells that are associated to connective
tissue-rich areas of the tonsil18, we employed a two-step
preparation process of cell suspensions involving mechanical
homogenization followed by collagenase digestion. We found that
the B19V-DNA loads were signiﬁcantly higher in the CD19þ
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Figure 2 | Antibody-dependent uptake of VP2-VLPs in B cell lines. The mean ﬂuorescence intensity (MFI) of VP2-VLP-AF647 was measured by ﬂow
cytometry in Raji (left column) and GM12878 cells (right column) after incubation with total puriﬁed B19V-positive (red line) or -negative IgGs (blue line,
squares) (a,b). Pooled sera from B19V-IgGþ individuals either heat inactivated (red solid line) or non-heat inactivated (red dotted line) or pooled sera from
B19V-IgG- individuals either heat inactivated (blue solid line, squares) or non-heat inactivated (blue dotted line) were used (c,d). * Represents statistical
signiﬁcance (Po0.001) between positive and respective negative controls at a given concentration. The effect on viral uptake was evaluated before (grey
bars) and after (black bars) blocking with an anti-CD32 antibody (e,f). The difference was statistically signiﬁcant (Raji Po0.001, GM12878 P¼0.05). Error
bars represent s.d. (of four replicates). Statistical signiﬁcance was calculated using Student’s t-test.
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cells released by collagenase, thus suggestive of persistence
in long-lived B cells. In contrast, the viral loads of another
B-cell infecting virus, Epstein-Barr19, showed no comparable
difference among preparations, thus not only precluding
a methodical bias as a reason for the results but also reﬂecting
the comparatively different life cycles of these two viruses. Indeed,
EBV regularly reactivates and constantly infects de novo B cells as
well as several other susceptible cell populations20.
We then sorted the CD19þ cells of individuals with the
highest B19V-DNA copy numbers based on their expression of
CD27 (memory) or IgD (naive) surface markers. However,
the overall low B19V-DNA quantities hampered any clear
resolution on the subtype of B cells harbouring the viral DNA.
Even though not representative of the cohort, substantial data
were derived solely from two individuals, ages 6 and 8, with
the highest B19V-DNA copy numbers, in whom the viral
DNA was found predominantly in a cluster of B cells expressing
high levels of both markers. It has been suggested that in
young children, germinal center-derived memory cells are
preferentially of IgM rather than of IgG type21. Thus, this
B-cell subpopulation may represent IgMþCD27þ IgDþ cells
which have been demonstrated to be of memory type and to
derive from common germinal center reactions as clonally
related, class switched, IgGþ memory B cells22. Of note,
the highest B19V-DNA copies in these two individuals were
found exceptionally in the monocyte fraction; yet they were
B19V-IgM negative and non-viremic, suggesting non-acute albeit
relatively recent primary infection.
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Figure 3 | Antibody-dependent enhancement of VP2-VLPs in primary B cells and in a monocytic cell line. The mean ﬂuorescence intensity (MFI) of
VP2-VLP-AF647 was measured by ﬂow cytometry in tonsillar B cells from two seronegative individuals (a,b) as well as in U937 cells (c) after incubation
with B19V-IgGþ (black solid line) or B19V-IgG- (black solid line, squares) total puriﬁed preparations. Error bars represent standard deviation (of four
replicates). *Represents statistical signiﬁcance (Po0.001) between positive and negative IgGs at a given concentration as calculated by Student’s t-test.
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We isolated CD19þ cells from venous blood of B19-seropositive
individuals, but found the blood-derived cells to be B19V-DNA
negative. This may reﬂect the rapid turnover of circulating B cells
(from a few days to 5–6 weeks)23 and/or their difference in
phenotype as compared to tonsillar B cells24,25.
Even though the deﬁnitive subset of the B19V-DNA-laden
B cells remains to be determined, the speciﬁc genotype of
B19V found provided compelling evidence of its persistence in
long-lived cells. Indeed, out of the three described viral genotypes,
the type 2 disappeared from circulation around 1970 (refs 3,4).
In our cohort, four individuals older than 45 years carried this
extinct virus type within their B cells, thus alluding to the
longevity of these cells. Indeed, since the B19V-DNA copy
numbers in tissue wane with time and there are no detectable
traces of the virus in blood or secretions other than during recent
infection, it is unlikely that continuous viral replication or
re-infection could explain the ﬁnding in B cells of a pathogen
that circulates no more11.
Although there are some isolated case reports of B19V-type 2
viremia, particularly in immunocompromised individuals26,27,
the extreme rarity of such events rules against regular replication
or re-activation of the persistent virus. Also, by molecular
data B19V replication has been reported to be slow or absent
during persistence28 and no evidence exists of B19V integration
into the host genome.
Thus, the common occurrence of the extinct type 2 B19V in our
ageing individuals suggests for these very B cells a survival time of
at least 40 to 60 years. This indicates that immunological memory
is not only maintained in the absence of antigen re-exposure29,30
but that it is due to long-term survival of original clones.
While the presence of B19V capsid proteins has been reported
in lymphoid cells of inﬂamed synovial tissue sections31,32, the
mechanism of virus uptake into B cells has never been examined.
We demonstrated the entry to be antibody mediated and
CD32 dependent using both synthetic VLPs and native viruses,
in line with a previous ﬁnding in monocytes15.
The CD32 receptor plays an important role in the down-
regulation of B-cell responses and its deﬁciency or reduced
expression correlates to prolonged humoral or autoimmune
reactivity33,34. Analogously, B19V-related arthropathies are
allegedly due to IgG deposition1 and this virus has been
proposed to play a role in triggering or exacerbating auto-
immune diseases35. Thus, our ﬁnding may provide a basis for the
prolonged B-cell activation and the sustained polyclonal antibody
production so characteristic of B19V acute infection35.
Moreover, B19V seropositivity has been correlated to speciﬁc
patterns of gene promoter DNA methylation in children’s B-cell
acute lymphoblastic leukaemia36. Even without evidence of
causality, it might be relevant to expand on the mechanisms by
which B19V could modulate the affected B cells and whether it
might play a role in the development of proliferative disorders.
In the present study, we (i) demonstrated a cellular site for
B19V lifelong tissue persistence, (ii) provided a marker for the
longevity of B cells based on the detection of a no longer
circulating virus type and (iii) documented antibody-dependent
enhancement as the uptake mechanism.
Methods
Tonsil collection and preparation. The right palatine tonsil and a serum sample
were collected from 77 patients each, who underwent tonsillectomy/tonsillotomy
for chronic tonsillitis or tonsillar hypertrophy during April-May 2015 at the
Department of Otorhinolaryngology-Head and Neck Surgery of Helsinki
University Hospital. The patients’ ages ranged from 2 to 69 years (mean 22).
The Ethics Committee of Surgery of Helsinki and Uusimaa Hospital District
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Figure 5 | Antibody-dependent uptake of native B19V in B cell lines. ADE was tested using viremic plasma in Raji (left column) and GM12878
(right column) cells in the presence of total puriﬁed B19V-positive or -negative IgGs (a,b). The effect on viral uptake was evaluated before (grey bars) and
after (black bars) blocking with an anti-CD32 antibody (c,d). Error bars represent s.d. (of three replicates). *Represents statistical signiﬁcance (Po0.001)
between positive and respective negative controls, as calculated by Student’s t-test.
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approved the study protocol. The patients provided written consent before entry
into the study.
The tonsils were collected immediately after surgery into tubes containing
PBS and were kept on ice through the preparations. They were cut into smaller
pieces with disposable scalpels and two separate tonsillar cell suspensions were
prepared by a two-step process consisting of: (i) mechanical homogenization
with a syringe plunge; (ii) collagenase digestion of the residual tonsillar tissue
(from the previous step) with 0.1mgml 1 Liberase TL (Roche) at þ 37 C for
30min. Each cell suspension was washed with 50ml PBS and ﬁltrated through
a 70 mm nylon mesh (Corning Life Sciences). Henceforth, each of the cell
suspensions were treated and analysed independently.
The B, T and monocyte/macrophage cell fractions were enriched using
anti-CD19, -CD3, -CD14 magnetic beads, respectively, following manufacturer’s
protocol (Invitrogen). The purity of the cell fractions was tested from six
individuals by incubation with a 1:100 dilution of anti-human CD19-FITC
(#MHCD1910, Invitrogen), CD3-PE/cy5.5 (#ab124052, Abcam) and CD14-PE
(#345785, BD Biosciences) on ice for 30min and analysed on a BD Accuri C6 Flow
cytometer.
Anti-mouse Ig, k/Negative control compensation particles set (#552843,
BD Biosciences) as well as corresponding ﬂuorescent-labelled isotypes served as
controls.
Lymphoid cell isolation from venous blood. Venous blood samples were
collected from one B19V-seronegative and seven seropositive staff members.
Informed consent was obtained form all study subjects and the study protocol was
approved by the Ethics Committee of the Helsinki and Uusimaa Hospital District.
The blood was collected using BD vacutainer CPT tubes (BD Biosciences) and the
PBMCs separated as instructed by the manufacturer. From this, the CD19þ cells
underwent magnetic cell separation as speciﬁed in the previous section.
DNA extraction and quantiﬁcation. The DNA from tonsillar cells was extracted
with the KingFisher Duo puriﬁcation system (12-sample format) using the
KingFisher Cell and Tissue DNA Kit (both Thermo Scientiﬁc) according to
manufacturer’s instructions. PBS (n¼ 2) was used as a negative control during
the extractions.
B19V DNA was quantiﬁed with (i) Pan-B19V qPCR amplifying a 154 bp region
of the NS1 gene and conﬁrmed with (ii) VP-qPCR targeting a 121-bp region of
the VP1 gene, as previously described11,37. The Pan-B19V qPCR products of the
33 positive individuals were puriﬁed with Difﬁnity RapidTip2 (Sigma-Aldrich) and
Sanger sequenced with corresponding qPCR forward and reverse primers at the
sequencing unit of the Institute for Molecular Medicine Finland. The sequences
were analysed with Bioedit v.7.2.5 (Ibis Biosciences) and compared to B19V
reference sequences (GenBank accession numbers FN598217.1 and AY044266.2 for
genotype 1 and 2, respectively) using BLAST.
EBV DNA was quantiﬁed with a qPCR modiﬁed from Aalto et al.38, targeting
the BALF5 DNA-polymerase gene. The EBV-qPCR reaction mix was composed of
12.5 ml of 2 Maxima Probe Master Mix (Thermo Scientiﬁc) with 0.03 mM of
ROX passive reference dye, 0.25 mM of both forward and reverse primers, 0.17 mM
of probe, 5 ml of template DNA and nuclease-free water in a ﬁnal volume of 25 ml.
The PCR program consisted of initial denaturation at 95 C for 10min, following
45 cycles of 95 C for 15 seconds and 60 C for 1min. The analytical sensitivity was
10 copies/reaction.
To normalize the viral DNA copies to the cell number, the human single-copy
gene RNase P was quantiﬁed as described37.
For quantiﬁcation and as a positive control, tenfold serial dilutions
(1E6–1E1 copies per ml) of the following plasmids were used: (a) a near-full-length
B19V genotype 1 genome without hairpin structures (cloned in-house)39;
(b) RNase P -qPCR amplicon obtained from Dr. Janet Butel40; and (c) EBV-qPCR
amplicon synthesized and cloned into the pIDTBlue vector by Integrated DNA
Technologies (50-CCCTGTTTATCCGATGGAATGACGGCGCATTTCTCGT
GCGTGTACACCGTCTCGAGTATGTCGTAGACATGGAAGTCCAGAGGG
CTTCCG-30).
Each sample was analysed in duplicate.
All primers and probes used in this study were ordered from Sigma Aldrich.
Detailed sequence information to be found in Supplementary Table 3.
Serological studies. The serostatus of the study subjects was determined with
in-house B19V-IgG and -IgM EIAs as described41,42. In brief, for the B19V-IgG
EIA, 45 ng per well of biotinylated B19-VP2-VLPs were coated onto streptavidin
coated plates using sample Diluent (#6111040, Anilabsystems, Finland). The serum
samples were diluted 1:200, tested in duplicate and detected with anti-human
IgG horseradish-peroxidase conjugated (Dako).
B19V-IgM antibodies were measured using an in-house IgM capture EIA as
described by Maple et al.42 Microtiter plate wells (Costar, Corning) were coated
with goat anti-human IgM (#55097, Cappel/MP Biomedicals) and blocked with
3% bovine serum albumin. The serum samples were diluted 1:200 in PBS-Tween
(PBST), tested in duplicate, followed by addition of 10 ng per well of biotinylated
B19-VP2-VLP. For detection, a 1:12,000 dilution of streptavidin horseradish-
peroxidase conjugate (Dako) was added.
Both EIAs were developed by addition of o-phenylenediamine dihydrochloride
(Dako) plus H2O2 and the absorbances read at 492 nm using a Labsystems
Multiscan EX (Thermo Fisher).
Cell sorting of primary tonsillar B cells. Collagenase-treated tonsillar cell
suspensions were stored at  196 C after homogenization. Samples from
12 individuals were washed twice with PBS after thawing to remove excess DMSO,
resuspended in 10% FBS-PBS solution for 10min at 4 C and stained with
1:100 dilution of anti -CD19-PE (#ab1168, Abcam), -CD27-FITC (#ab30366,
Abcam), -IgD-APC (#561303, BD Pharmingen) on ice in the dark for 30min,
washed three times with PBS and immediately sorted in a BD Inﬂux ﬂow cytometer
cell sorter.
As controls and for compensation, unstained cells, single antibodies and
corresponding ﬂuorescent-isotype controls plus anti-mouse Ig, k/Negative
control compensation particles (BD Biosciences) were used.
The sorting was based on gated CD19þ cells and four cell subpopulations
were collected in PBS according to the expression of either CD27 or IgD markers
as: CD27þ IgD-, CD27þ IgDlow, CD27þ IgDhigh and CD27- IgDþ . The
B19V-DNA copies were quantiﬁed from each of these subpopulations as
speciﬁed above.
Cell lines. Two human B-cell lines (GM12878 and Raji (GM04671) cells, both
from Coriell Institute) and a monocytic cell line, U937 (ATCC CRL-1593.2),
were cultured in RPMI 1640þGlutaMAX-I medium (Gibco), 1% penicillin-
streptomycin (Sigma-Aldrich) and complement-inactivated 10% FBS (Gibco)
at þ 37 C and 5% CO2.
Primary tonsillar B cells from two seronegative individuals of the study cohort
were isolated with anti-CD19 magnetic beads from frozen total cell suspensions
of mechanically homogenized preparations and released with DETACHaBEAD
as instructed by manufacturer (Invitrogen).
Serum pools and puriﬁed human immunoglobulins. Two negative pools and
a positive pool of sera (n¼ 5, each) were tested before and after complement
inactivation.
Total immunoglobulin G was puriﬁed from a B19V-IgG negative pool (n¼ 4),
using the HiTrap Protein A HP column (GE Healthcare) according to
manufacturer’s instructions. The ﬁnal IgG concentration was measured with the
Pierce BCA protein assay kit (Thermo Fisher Scientiﬁc) following manufacturer’s
protocol.
A total puriﬁed IVIG preparation (Gammagard S/D, Baxter), of known
B19V reactivity as per in-house EIA, served as positive control.
Both puriﬁed IgG preparations were complement inactivated.
Antibody-dependent enhancement. The effect of B19V speciﬁc IgGs in the
internalization of VP2 VLP was tested on GM12878, Raji and U937 cell lines
as well as on primary tonsillar B cells from two B19V-seronegative individuals.
B19-VLPs consisting of the VP2 capsid protein were produced with the
BaculoGold Baculovirus Expression System (BD Biosciences) and conjugated to
Alexa Fluor 647 using a protein labelling kit (Thermo Fisher Scientiﬁc) according
to manufacturer’s protocol. The immunoreactivity and purity of the VP2-VLP-
AF647 were assessed by in-house EIA and SDS-PAGE followed by ﬂuorescence
imaging in Odyssey (LI-COR), respectively.
In each well, 1.50E5 of cells were cultured with 100 ng of VP2-VLP-AF647 and
incubated with either puriﬁed human IgGs or pooled sera. The puriﬁed human
IgGs were used at ﬁnal concentrations of 1, 0.5, 0.1, 0.05 or 0.01mgml 1 while the
serum pools, with or without heat inactivation, were tested at dilutions of 1:10,
1:50, 1:100, 1:500 or 1:1,000. The uptake was evaluated at different time points up
to 16 h, which was then used as the standard time point for this ADE experiments.
All conditions were tested in four replicates in the same plate and in at least
two separate occasions. Cells only and cells combined with VP2-VLP-AF647
(without antibodies) were used as controls through the studies.
ADE was also tested in the B-cell lines using live B19V from acute infection
plasma. To this end, 5E6 cells were incubated with 10 B19V particles per cell for
40 h together with 1mgml 1 of either B19V-positive or -negative total puriﬁed
human IgGs. All tests were carried out in triplicate and on two or more separate
occasions.
Following overnight incubation, the cells were washed with cold PBS, incubated
with 0.25% trypsin-EDTA (Gibco) for 15min at þ 37 C, washed three times with
cold 20% FBS-PBS and ﬁnally resuspended into PBS.
The efﬁciency of trypsin digestion was assessed by ﬂow cytometry via
expression of CD19-FITC (#MHCD1901, Invitrogen) and CD71-FITC (#555536,
BD Pharmingen) as well as of cell viability with propidium iodide (Invitrogen).
After trypsin digestion, ADE was determined in the VP2-VLP-AF647 treated
cultures by measuring the mean AF647 ﬂuorescence signal with BD Accuri C6 ﬂow
cytometer (BD Biosciences).
With live B19V, DNA from the cell cultures was extracted with the DNA Blood
Mini Kit (Qiagen) according to the manufacturer’s instructions for viral DNA,
and the B19V and RNase P copies were quantiﬁed by the respective qPCRs
(Pan-B19V and RNase P), as speciﬁed in DNA extraction and quantiﬁcation.
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Blocking of Fc-receptor. A total of 3E6 Raji or GM12878 cells were pre-incubated
with 20mgml 1 of anti-CD32 (#551900, BD Biosciences) for 1 h at þ 37 C, then
distributed to 1E5 cells per well and incubated with 100 ng of VP2-VLP-AF647
overnight. Cells alone and cells with VLPs only were used as controls.
In the assays with live B19V, 2E6 Raji or GM12878 cells were pre-incubated
with 40 mgml 1 of anti-CD32 (BD Biosciences) for 1 h at þ 37 C, and then
incubated with the live virus at 10 B19V particles per cell and 5E5 cells per well, in
the presence of 1mgml 1 of puriﬁed IgGs. After 40 h, the cells were washed and
trypsinized as described above.
Confocal microscopy. VLP internalization and co-localization with intracellular
structures was assessed by confocal microscopy.
After measurement of AF647 by ﬂow cytometry, the cells were spread and
air-dried on Zeiss high-performance cover slips and ﬁxed with 4% paraformal-
dehyde (PFA; 20min at room temperature). Early endosomal vesicles were
detected with a 1:150 dilution of EEA1 mouse monoclonal antibody (#610457,
BD Biosciences), and the DNA stained during embedding with DAPI
(4’-6-diamidino-2-phenylindole; Thermo Fisher Scientiﬁc), containing ProLong
antifade compound. Imaging was done using an Olympus FV-1000 inverted
confocal microscope (Olympus) with the UPLSAPO  60 oil-immersion objective
(numerical aperture¼ 1.35). Alexa 647 was excited with a 633 nm He-Ne laser and
the ﬂuorescence collected with a BA650IF long-pass ﬁlter. Alexa 488-conjugated
anti-rabbit IgG was excited with a 488 nm argon laser and its emission detected
with a 500 to 555 nm band-pass ﬁlter. DAPI was excited with a 405 nm diode laser
and detected with a 425 to 475 nm band-pass ﬁlter. For 3D image stacks, 320 320
pixels were collected from an appropriate depth depending on the sample. Pixel
resolution was adjusted toB70 nm per pixel in x and y dimensions, and to 150 nm
in the z dimension. Iterative deconvolution was performed with a signal-to-noise
ratio set at 5 and a quality threshold set at 0.05, using Huygens Essential software
(SVI). Image analysis was done with ImageJ43.
Immunolabelling of cell surface markers. The expression of Fc and globoside
receptors was assessed on cultured Raji and GM12878 cells, as well as on CD19þ
cells isolated from tonsillar tissue and venous blood. Brieﬂy, 1E6 cells were incu-
bated with 5 mgml 1 (1:100 dilution) of either mouse anti-human-CD32
(#551900, BD Pharmingen) or -CD64 antibodies (#55525, BD Pharmingen) on
ice for 30min, washed three times with PBS and incubated with 5 mgml 1
(1:100 dilution) of goat anti-mouse IgM/IgG-FITC secondary antibody
(#555988, BD Biosciences) for 30mins on ice and washed three times before
analysis on BD C6 Accuri.
The staining of globoside was done in a similar fashion using a 1:50 dilution of
rabbit polyclonal anti-globoside GL4 (#1960, Matreya LLC) and 5 mgml 1
(1:100 dilution) of goat anti-rabbit-FITC conjugated secondary antibody
(#554020, BD Biosciences).
The antibody concentrations were optimized before analysis and both unstained
cells as well as cells stained with secondary antibody only were used as background
controls.
Statistical analysis. The median CI was calculated with normal approximation
using OpenEpi v3 open source calculator. SPSS v22.0 was used to calculate the
Mann-Whitney U asymptotic sig. (two-sided test) and Pearson’s w2-test. The dif-
ference in mean ﬂuorescence intensity in the ADE experiments was calculated with
Student’s t-test in RStudio (v3.2.4).
Data availability. All the relevant data are available from the corresponding
author upon request.
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